LXRX Dividend: Lexicon Pharmaceuticals Inc Yield Insights

Income

Balance sheet

Cash flow

Annual

Quarterly

LXRX Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	70	31	1	0	0	24
Revenue Growth (YoY)	1,300%	3,000%	--	--	-100%	-93%
Cost of Revenue	0	0	0	0	0	1
Gross Profit	70	30	1	0	0	22
Selling, General & Admin	60	143	113	48	32	47
Research & Development	76	84	58	52	55	153
Operating Expenses	137	227	172	100	87	200
Other Non Operating Income (Expenses)	8	12	7	1	0	2
Pretax Income	-68	-200	-177	-101	-87	-58
Income Tax Expense	--	--	--	--	0	0
Net Income	-68	-200	-177	-101	-87	-58
Net Income Growth	-69%	13%	75%	16%	50%	-145%
Shares Outstanding (Diluted)	363.39	320.03	221.13	165.7	145.7	110.8
Shares Change (YoY)	1%	45%	33%	14%	32%	-5%
EPS (Diluted)	-0.18	-0.62	-0.8	-0.62	-0.6	-0.53
EPS Growth	-68%	-22%	28.99%	3%	13%	-148%
Free Cash Flow	-72	-179	-162	-90	-88	-143
Free Cash Flow Per Share	-0.19	-0.55	-0.73	-0.54	-0.6	-1.29
Gross Margin	100%	96.77%	100%	0%	0%	91.66%
Operating Margin	-94.28%	-635.48%	-17,100%	0%	0%	-741.66%
Profit Margin	-97.14%	-645.16%	-17,700%	0%	0%	-241.66%
Free Cash Flow Margin	-102.85%	-577.41%	-16,200%	0%	0%	-595.83%
EBITDA	-66	-197	-171	-100	-87	-176
EBITDA Margin	-94.28%	-635.48%	-17,100%	0%	0%	-733.33%
D&A For EBITDA	0	0	0	0	0	2
EBIT	-66	-197	-171	-100	-87	-178
EBIT Margin	-94.28%	-635.48%	-17,100%	0%	0%	-741.66%
Effective Tax Rate	--	--	--	--	0%	0%